Immunohistochemical Marker Patterns in Female Breast Cancer
DOI:
https://doi.org/10.3889/oamjms.2022.8950Keywords:
Breast cancer, Immunohistochemistry, Molecular subtypes, BulgariaAbstract
BACKGROUND: Breast cancer (BC) represents the most common cancer in women worldwide and in Bulgaria. Its great medico-social importance determines the intensive complex research devoted to BC prevention, early diagnosis and management.
AIM: The objective of the present investigation is to reveal some essential peculiarities of four main immunohistochemical markers used in the diagnosis of molecular subtypes of female BC.
MATERIALS AND METHODS: During the period between December 1, 2017 and November 30, 2020, we examined a total of 128 randomly selected female BC patients operated on in Marko Markov Specialized Hospital for Active Treatment of Oncological Diseases of Varna, Bulgaria. We analyze BC molecular types and four immunohistochemical markers in BC patients. The expression of estrogen (ER) and progesterone (PR) receptors is assessed in mammary gland biopsies and surgical specimens by using the indirect immunoperoxidase method with EnVision™ FLEX MiniKit, that of HER2 with HercepTest™ and that of Ki-67 proliferation index with Leica Aperio Scan Scope AT2 device. The positivity and negativity of these receptors in single molecular subtypes is evaluated.
RESULTS: The luminal B HER2-positive and the luminal B HER2-negative subtypes are most common - in 36.72% and 35.16% of the cases, respectively. TNBC subtype is established in 11.72%) the luminal A - in 8.59% and the non-luminal HER2-positive subtype - in 7.81% of the cases. The positive expression is statistically significantly more common in ER (t=8.972; p<0.0001) and PR (t=2.828; p<0.01), while the negative expression insignificantly prevails in HER2.
CONCLUSION: Our immunohistochemical results in female BC patients prove the role of single receptor expression for the proper and timely decision making about the necessity and benefit of additional chemotherapy in selected surgically treated cases.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-69. https//doi.org/10.1016/S0140-6736(20)32381-3 PMid:33812473
Ma Y, Liu A, O’Connell AM, Zhu Y, Li H, Han P, et al. Contrast-enhanced cone beam breast CT features of breast cancers: Correlation with immunohistochemical receptors and molecular subtypes. Eur Radiol. 2021;31(4):2580-9. https//doi.org/10.1007/s00330-020-07277-8 PMid:33009590
Wang S, Wang Z, Li R, You C, Mao N, Jiang T, et al. Association between quantitative and qualitative image features of contrast-enhanced mammography and molecular subtypes of breast cancer. Quant Imaging Med Surg. 2022;12(2):1270-80. https//doi.org/10.21037/qims-21-589 PMid:35111622
Ueda D, Yamamoto A, Takashima T, Onoda N, Noda S, Kashiwagi S, et al. Training, validation, and test of deep learning models for classification of receptor expressions in breast cancers from mammograms. JCO Precis Oncol. 2021;5:543-51. https//doi.org/10.1200/PO.20.00176 PMid:34994603
Kwon HW, Lee JH, Pahk K, Park KH, Kim S. Clustering subtypes of breast cancer by combining immunohistochemistry profiles and metabolism characteristics measured using FDG PET/CT. Cancer Imaging. 2021;21(1):55. https//doi.org/10.1186/s40644-021-00424-4 PMid:34579791
Kim JJ, Kim JY, Suh HB, Hwangbo L, Lee NK, Kim S, et al. Characterization of breast cancer subtypes based on quantitative assessment of intratumoral heterogeneity using dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging. Eur Radiol. 2022;32(2):822-33. https//doi.org/10.1007/s00330-021-08166-4 PMid:34345946
Gao W, Yang Q, Li X, Chen X, Wei X, Diao Y, et al. Synthetic MRI with quantitative mappings for identifying receptor status, proliferation rate, and molecular subtypes of breast cancer. Eur J Radiol 2022;148:110168. https//doi.org/10.1016/j.ejrad.2022.110168 PMid:35078137
Yaneva G, Maslarski I. Immunohistochemical Study of Female Breast Cancer in Varna, Bulgaria. Bulgaria: Proceeding CR Academic Bulgarian Science; 2022.
Vučković L, Klisic A, Raonić J, Vučinić J. Comparative study of immunohistochemical determination of breast cancer molecular subtypes on core biopsy and surgical specimens. Eur Rev Med Pharmacol Sci. 2021;25(11):3990-6. https//doi.org/10.26355/eurrev_202106_26039 PMid:34156676
Li C, Fan Z, Lin X, Cao M, Song F, Song F. Parity and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis. Cancer Epidemiol. 2021;75:102050. https//doi.org/10.1016/j.canep.2021.102050 PMid:34706325
Kumar S, Bal A, Das A, Bhattacharyya S, Laroiya I, Khare S, et al. Molecular subtyping of triple negative breast cancer by surrogate immunohistochemistry markers. Appl Immunohistochem Mol Morphol. 2021;29(4):251-7. https//doi.org/10.1097/PAI.0000000000000897 PMid:33337632
Kong H, Bai Q, Li A, Zhou X, Yang W. Characteristics of HER2- negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline. Diagn Pathol. 2022;17(1):5. https//doi.org/10.1186/s13000-021-01187-z PMid:34996485
Sharma JD, Khanna S, Ramchandani S, Kakoti LM, Baruah A, Mamidala V. Prevalence of molecular subtypes of breast carcinoma and its comparison between two different age groups: A retrospective study from a tertiary care center of Northeast India. South Asian J Cancer. 2021;10(4):220-4. http//doi.org/10.1055/s-0041-1731905 PMid:34984199
Mthembu JG, Bhuiyan M. Profile of molecular subtyping of breast cancer and clinicopathological features in Mankweng Hospital breast oncology clinic, Limpopo Province, South Africa. S Afr Med J. 2021;111(11b):1132-5. https//doi.org/10.7196/SAMJ.2021.v111i11b.16104 PMid:34949236
Macari A, Soberanis-Pina P, Varela-Santoyo E, Valle-Sanchez MA, Leal-Hidalgo JL, Torres-Guillen VM, et al. Prevalence and molecular profile of breast carcinoma using immunohistochemistry markers in Mexican women. World J Oncol. 2021;12(4):119-23. https//doi.org/10.14740/wjon1392 PMid:34349856
Hjerkind KV, Johansson AL, Trewin CB, Russnes HG, Ursin G. Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway. Breast Cancer Res. 2022;24(1):4. https//doi.org/10.1186/s13058-021-01498-5 PMid:35012613
Hartung C, Porsch M, Stückrath K, Kaufhold S, Staege MS, Hanf V, et al. Identifying high-risk triple-negative breast cancer patients by molecular subtyping. Breast Care (Basel). 2021;16(6):637-47. https//doi.org/10.1159/000519255 PMid:35082572
Gupta P, Singh V, Kumar S, Das A, Singh G, Bal A. Breast cancer stem cell population in different molecular subtypes of breast cancer. Breast Dis. 2022;41(1):199-203. https//doi.org/10.3233/BD-210050 PMid:35068436
Pavanelli AC, Mangone FR, Yoganathan P, Bessa SA, Nonogaki S, De Toledo Osório CA, et al. Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with luminal A and B breast cancer subtypes. Breast Cancer Res Treat. 2022;192(1):43-52. https//doi.org/10.1007/s10549-021-06452-9 PMid:35031902
Pereira C, Martis M, D’Souza R, Tauro LF. Correlation of clinicopathological features of breast cancer with molecular subtypes taking Ki-67 into consideration: Single institution experience over 5 years. Curr Health Sci J. 2021;47(3):348-52. https//doi.org/10.12865/CHSJ.47.03.03 PMid:35003765
Mushtaq M, Chaudry SS, Sheikh AK, Khan N, Khattak A, Akbar A, et al. Comparison of different molecular subtypes with 14% Ki-67 cut-off threshold in breast cancer patients of Pakistan-an indication of poor prognosis. Arch Iran Med. 2021;24(11):837-44. https//doi.org/10.34172/aim.2021.124 PMid:34841829
Abdel-Rahman MA, Mahfouz M, Habashy HO. RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance. Diagn Pathol. 2022;17(1):1. https//doi.org/10.1186/s13000-021-01174-4 PMid:34986845
Bergamino MA, Morani G, Parker J, Schuster EF, Leal MF, López-Knowles E, et al. Impact of duration of neoadjuvant aromatase inhibitors on molecular expression profiles in estrogen receptor-positive breast cancers. Clin Cancer Res. 2022;28(6):1217-28. https//doi.org/10.1158/1078-0432.CCR-21-2718 PMid:34965950
Liu YL, Hsu CY, Feng CJ, Lien PJ, Huang CC, Lin YS, et al. Clinical impacts of molecular subtyping by multigene assay on hormone receptor positive breast cancers. J Chin Med Assoc. 2022;85(3):324-30. https//doi.org/10.1097/JCMA.0000000000000657 PMid:34907993
Utsumi T, Kobayashi N, Hikichi M, Ushimado K, Kuroda M. Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and-negative subtypes. Fujita Med J. 2021;7(4):130-5. https//doi.org/10.20407/fmj.2020-023 PMid:35111557
Downloads
Published
How to Cite
License
Copyright (c) 2022 Galina Yaneva, Tsonka Dimitrova, Dobri Ivanov, Gergana Ingilizova, Sergei Slavov (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
